申请人:IMPERIAL CHEMICAL INDUSTRIES PLC
公开号:EP0065407A2
公开(公告)日:1982-11-24
The invention provides a pharmaceutical composition comprising an aldose reductase inhibitory 1'-substituted-spiro[pyrrolidine-3,3'-indoline]-2,2', 5-trione of the formula:
wherein Ra is (2-7 C) alkyl or (3-7 C) alkenyl, naphthylmethyl or cinnamyl optionally bearing one or two halogeno nuclear substituents, or Ra is benzyl optionally bearing one or two sub- stltuents and benzene ring A optionally bears one or two substituents, trifluoromethyl and nitro; or a salt thereof with a base affording a pharmaceutically acceptable cation; or a non-toxic, biodegradable precursor thereof; together with a pharmaceutically a-ceptable diluent or carrier. The invention also provides novel compounds of formula I and processes for their manufacture.
The compositions are of application in the treatment or prophylaxis of the side effects of diabetes or galactosemia.
本发明提供了一种药物组合物,该组合物包含式 1'-取代-螺[吡咯烷-3,3'-吲哚啉]-2,2', 5-三酮的醛糖还原酶抑制剂:
其中Ra为(2-7 C)烷基或(3-7 C)烯基、萘甲基或肉桂基,可选带有一个或两个卤代核取代基,或Ra为苄基,可选带有一个或两个亚取代基,苯环A可选带有一个或两个取代基、三氟甲基和硝基;或其与碱的盐,生成药学上可接受的阳离子;或其无毒、可生物降解的前体;连同药学上可接受的稀释剂或载体。本发明还提供了新型的式 I 化合物及其生产工艺。
这些组合物可用于治疗或预防糖尿病或半乳糖血症的副作用。